MYGN Stock Overview
A genetic testing and precision medicine company, develops genetic tests in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Myriad Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.35 |
| 52 Week High | US$25.95 |
| 52 Week Low | US$13.82 |
| Beta | 1.97 |
| 1 Month Change | 14.79% |
| 3 Month Change | 0.54% |
| 1 Year Change | -0.49% |
| 3 Year Change | -23.82% |
| 5 Year Change | -7.42% |
| Change since IPO | 315.81% |
Recent News & Updates
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
May 11
Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report
May 09Recent updates
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
May 11Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report
May 09Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?
Mar 28An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued
Feb 02Myriad Genetics' Strategic Growth Fuels Bullish Outlook
Jan 31Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price
Dec 18Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?
Aug 07Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)
Apr 13Myriad: Trying To Find Its Footing In An Evolving Industry
Sep 26Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system
Aug 25Are Investors Undervaluing Myriad Genetics, Inc. (NASDAQ:MYGN) By 50%?
Aug 05Myriad Genetics Q2 2022 Earnings Preview
Aug 03Myriad Genetics touts study results of GeneSight test on depression remission rates
Jul 12Shareholder Returns
| MYGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.5% | 0.6% | -0.6% |
| 1Y | -0.5% | 6.3% | 22.4% |
Return vs Industry: MYGN underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: MYGN underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| MYGN volatility | |
|---|---|
| MYGN Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MYGN has not had significant price volatility in the past 3 months.
Volatility Over Time: MYGN's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 2,700 | Paul Diaz | www.myriad.com |
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Myriad Genetics, Inc. Fundamentals Summary
| MYGN fundamental statistics | |
|---|---|
| Market cap | US$2.06b |
| Earnings (TTM) | -US$234.60m |
| Revenue (TTM) | US$774.20m |
2.6x
P/S Ratio-8.6x
P/E RatioIs MYGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYGN income statement (TTM) | |
|---|---|
| Revenue | US$774.20m |
| Cost of Revenue | US$241.60m |
| Gross Profit | US$532.60m |
| Other Expenses | US$767.20m |
| Earnings | -US$234.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.59 |
| Gross Margin | 68.79% |
| Net Profit Margin | -30.30% |
| Debt/Equity Ratio | 5.1% |
How did MYGN perform over the long term?
See historical performance and comparison